Novartis
NVS
NVS
1,136 hedge funds and large institutions have $18.2B invested in Novartis in 2022 Q1 according to their latest regulatory filings, with 93 funds opening new positions, 413 increasing their positions, 413 reducing their positions, and 87 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,136
Holders Change
-7
Holders Change %
-0.61%
% of All Funds
17.98%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
93
Increased
413
Reduced
413
Closed
87
Calls
$347M
Puts
$228M
Net Calls
+$119M
Net Calls Change
-$291M
Top Buyers
| 1 |
Sanders Capital
West Palm Beach,
Florida
|
+$99.7M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$88.7M |
| 3 |
Goldman Sachs
New York
|
+$52.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$45.9M |
| 5 |
CCM
Cullen Capital Management
New York
|
+$43.2M |
Top Sellers
| 1 |
Franklin Resources
San Mateo,
California
|
-$168M |
| 2 |
D.E. Shaw & Co
New York
|
-$118M |
| 3 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
-$112M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$87.9M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$51.5M |
